Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Johnson and Johnson
AstraZeneca
Dow
McKinsey

Last Updated: December 3, 2022

Details for Patent: 7,754,230


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,754,230 protect, and when does it expire?

Patent 7,754,230 protects KYBELLA and is included in one NDA.

This patent has sixty-eight patent family members in twenty-two countries.

Summary for Patent: 7,754,230
Title:Methods and related compositions for reduction of fat
Abstract: Compositions and methods useful in the reduction of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.
Inventor(s): Kolodney; Michael S. (Santa Monica, CA), Rotunda; Adam M. (Los Angeles, CA)
Assignee: The Regents of the University of California (Oakland, CA) Los Angeles Biomed. Res. Inst. at Harbor UCLA Medical Center (Torrance, CA)
Application Number:11/134,727
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,754,230
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,754,230

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kythera Biopharms KYBELLA deoxycholic acid SOLUTION;SUBCUTANEOUS 206333-001 Apr 29, 2015 AP RX Yes Yes See Plans and Pricing See Plans and Pricing METHOD FOR REDUCTION OF SUBMENTAL FAT See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,754,230

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 518565 See Plans and Pricing
Austria 521355 See Plans and Pricing
Australia 2005245002 See Plans and Pricing
Canada 2567298 See Plans and Pricing
China 101018553 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
McKinsey
Merck
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.